查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1759485

青蒿琥酯注射剂的全球市场:纯度·用途·终端用户·通路·各地区 (～2032年)

Global Artesunate Injection Market Research Report Information by Purity, by Application, by End User, by Distribution Channel, by Region Industry Forecast till 2032
出版日期: | 出版商: Market Research Future | 英文 107 Pages | 订单完成后即时交付

价格

预计全球青蒿琥酯注射剂市场规模将从 2023 年的约 8,500 万美元增长至 2024-2032 年预测期内的 0.9% 的中等复合年增长率。

主要成长动力包括疟疾盛行率的上升、对速效注射疗法的日益青睐以及生产和分销系统的进步。此外，透过全球宣传活动提高认识和早期诊断也对提高治疗率产生了积极影响。

然而，一些阻碍因素阻碍了市场潜力的发挥。高昂的生产和治疗成本、部分地区供应不稳定以及严格的监管审批程序都是阻碍因素。此外，复杂的智慧财产权问题以及来自其他抗疟药物的竞争也对市场成长带来压力。

儘管存在这些阻碍因素，但仍存在成长机会。例如，远距医疗平台的普及正在扩大疟疾流行地区偏远地区诊断和治疗的可近性。此外，加强公私合作正在增加对疟疾相关医疗解决方案的资金投入。此外，区域製造基地的发展有助于稳定供应链，医疗基础设施的整体发展也有助于提高青蒿琥酯注射的可近性。

区域展望

随着全球健康意识的增强，北美对青蒿琥酯注射的需求正在增长。这主要是由于前往疟疾流行地区的旅行者人数增加。儘管加拿大和美国没有地方性疟疾感染，但海外输入病例呈现增加趋势，因此需要获得青蒿琥酯这种快速有效的治疗方法，以防止病情恶化。

在欧洲，青蒿琥酯已被欧洲药品管理局 (EMA) 认可为治疗重症疟疾的高效药物，并已被许多国家纳入国家治疗指南。然而，监管复杂性和成本方面的课题仍然存在，限制了该药物在该地区更广泛的应用。

在亚太地区，随着世界卫生组织 (WHO) 推荐青蒿琥酯作为重症疟疾的一线治疗药物，青蒿琥酯的推广应用正在不断扩大。根据这项建议，青蒿琥酯已被正式纳入疟疾流行国家的官方医疗方案，其在临床实践中的应用也正在不断扩大。

在南美洲，秘鲁、巴西和哥伦比亚等亚马逊国家疟疾感染率居高不下，这使得青蒿琥酯成为国家疟疾控制计画的重要组成部分，尤其是在重症疟疾患者中。

中非国家，尤其是刚果民主共和国，疟疾发生率极高，因此青蒿琥酯成为重要的第一线治疗药物。

本报告提供全球青蒿琥酯注射剂的市场调查，彙整市场定义和概要，市场成长的各种影响因素分析，市场规模的转变·预测，各种区分·地区/各主要国家的明细，竞争环境，主要企业简介等资讯。

目录

第1章 摘要整理

第2章 市场概要

第3章 调查手法

第4章 市场动态

  • 促进因素
    • 疟疾盛行率上升
    • 注射剂治疗需求增加
    • 製造和分销技术的进步
    • 提高认识和教育水平
  • 阻碍因素
    • 注射用青蒿琥酯成本高
    • 注射用青蒿琥酯成本高
    • 监理课题与漫长的审批流程
    • 智慧财产权和专利问题
    • 与其他抗疟药的竞争药物
  • 机会
    • 远距医疗：扩大医疗服务，提高偏远地区诊断和治疗的可近性
    • 增加对疟疾研究的公私合作资金
    • 开发联合疗法，提高治疗效果
    • 区域製造中心的出现，增强供应链
    • 对整体医疗保健产业的影响
    • 对全球青蒿琥酯注射市场的影响
    • 对青蒿琥酯注射市场供应链的影响
    • 对青蒿琥酯注射市场需求的影响
    • 对青蒿琥酯注射剂市场价格的影响

第5章 市场要素分析

  • 供应链分析
  • 波特的五力分析

第6章 全球青蒿琥酯注射剂市场:纯度

  • 青蒿琥酯0.99
  • 青蒿琥酯0.98

第7章 全球青蒿琥酯注射剂市场:各用途

  • 疟疾
  • 重病疟疾
  • 脑疟疾
  • 併发症的没有的疟疾

第8章 全球青蒿琥酯注射剂市场:各终端用户

  • 医院
  • 诊所
  • 药局
  • 政府机关
  • 非官方机构

第9章 全球青蒿琥酯注射剂市场:各流通管道

  • 直销
  • 销售商及批发商
  • 零售药局
  • 线上销售

第10章 全球青蒿琥酯注射剂市场:各地区

  • 概要
  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东·非洲

第11章 竞争情形

  • 市场占有率分析
  • 竞争仪表板
  • 主要的展开·成长策略

第12章 企业简介

  • AMIVAS
  • ADVACARE PHARMA
  • ZYDUS CADILA
  • INTAS PHARMACEUTICAL
  • SYSTACARE REMEDIES
  • LEXICARE PHARMA
  • CIPLA
  • GUILIN PHARMA
  • IPCA LABORATORIES
  • WATRAN PHARMACEUTICALS PVT. LTD
Product Code: MRFR/HC/38057-HCR

Global Artesunate Injection Market Research Report Information by Purity (Artesunate 0.99, Artesunate 0.98), by Application (Malaria, Severe Malaria, Cerebral Malaria, Uncomplicated Malaria, Other Applications), by End User (Hospitals, Clinics, Pharmacies, Government Institutions, Non-Governmental Organizations), by Distribution Channel (Direct Sales, Distributors and Wholesalers, Retail Pharmacies, and Online Sales), by Region (North America, Europe, APAC, South America, MEA) Industry Forecast till 2032

Market Analysis

In 2023, the global artesunate injection market reached a valuation of approximately USD 85 million. From 2024 to 2032, the market is anticipated to grow at a modest compound annual growth rate (CAGR) of 0.9%. Key growth factors include the increasing burden of malaria, the rising preference for injectable therapies that offer rapid action, and advancements in manufacturing and distribution systems. In addition, improved awareness and early diagnosis due to global education initiatives have positively influenced treatment rates.

However, several limitations hinder the market's potential. High production and treatment costs, inconsistent availability in various regions, and stringent regulatory approval processes create roadblocks. Complex intellectual property issues and competition from alternative antimalarial drugs also add pressure to market growth.

Despite these restraints, opportunities exist. The rise of telehealth platforms is helping expand access to diagnosis and treatment in remote, malaria-affected regions. Furthermore, increased collaboration between public and private sectors is resulting in greater funding for malaria-related healthcare solutions. The development of regional manufacturing centers is improving supply chain stability, and general progress in healthcare infrastructure is facilitating better access to artesunate injections. Together, these trends are shaping market dynamics and influencing future pricing, accessibility, and overall demand for artesunate therapies.

Industry Segmentation

Depending on the purity type, the global artesunate injection market is divided into Artesunate 0.99 and Artesunate 0.98.

The global artesunate injection market is divided into end user industry, such as hospitals, clinics, pharmacies, government institutions, non-governmental organizations.

The application type of the global market comprises malaria, severe malaria, cerebral malaria, uncomplicated malaria, other applications.

Based on the distribution channel, the global market has been categorized into direct sales, distributors and wholesalers, retail pharmacies, and online sales.

In terms of regions, the global market comprises, Middle East & Africa, Europe, North America, South America, and Asia Pacific.

Regional Perspectives

In North America, increasing global health awareness has contributed to rising demand for artesunate injections, primarily due to the growing number of travelers visiting malaria-endemic countries. Although malaria is not endemic in Canada or the United States, the region has witnessed a rise in imported cases, necessitating access to rapid and effective treatments like artesunate to prevent severe complications.

In Europe, artesunate has gained recognition from the European Medicines Agency (EMA) as a highly effective treatment for severe malaria. Consequently, many countries have incorporated it into their national treatment guidelines. However, regulatory complexities and cost-related challenges still limit its broader use across the continent.

The Asia-Pacific region has seen expanded adoption of artesunate, largely driven by the World Health Organization's (WHO) recommendation endorsing it as the first-line treatment for severe malaria. This has led to its inclusion in official healthcare protocols throughout malaria-prone nations in the region.

In South America, nations within the Amazon Basin, including Peru, Brazil, and Colombia, continue to experience high rates of malaria transmission. Artesunate plays a crucial role in national malaria response programs, especially for severe infections.

Central African countries like the Democratic Republic of the Congo (DRC) face a heavy malaria burden, where artesunate remains an essential component of frontline treatment.

Major Competitors

Cipla, Guilin Pharma, IPCA Laboratories, AMIVAS, Advacare Pharma, Zydus Cadila, Intas Pharmaceutical, Systacare Remedies, Lexicare Pharma, Watran Pharmaceuticals Pvt. Ltd. are the leading companies in the Global Artesunate Injection Market Research.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 DATA MINING PROCESS
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 SECONDARY RESEARCH DATA FLOW:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 PRIMARY RESEARCH DATA FLOW:
    • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
    • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
  • 3.6 APPROACHES FOR MARKET END USER ESTIMATION:
    • 3.6.1 REVENUE ANALYSIS APPROACH
    • 3.6.2 DATA FORECASTING
    • 3.6.3 DATA FORECASTING TECHNIQUE
  • 3.7 DATA MODELING
    • 3.7.1 MICROECONOMIC FACTOR ANALYSIS:
    • 3.7.2 DATA MODELING:
  • 3.8 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 INCREASING PREVALENCE OF MALARIA
    • 4.2.2 GROWING DEMAND FOR INJECTABLE TREATMENTS
    • 4.2.3 ADVANCEMENTS IN MANUFACTURING AND DISTRIBUTION
    • 4.2.4 GROWING AWARENESS AND EDUCATION
  • 4.3 RESTRAINTS
    • 4.3.1 HIGH COST OF ARTESUNATE INJECTIONS
    • 4.3.2 LIMITED AVAILABILITY IN CERTAIN REGIONS
    • 4.3.3 REGULATORY CHALLENGES AND LENGTHY APPROVAL PROCESSES
    • 4.3.4 INTELLECTUAL PROPERTY AND PATENT ISSUES
    • 4.3.5 COMPETING ANTIMALARIAL THERAPIES
  • 4.4 OPPORTUNITY
    • 4.4.1 EXPANSION OF TELEHEALTH SERVICES FOR REMOTE DIAGNOSIS AND TREATMENT
    • 4.4.2 INCREASED PUBLIC-PRIVATE PARTNERSHIPS FOR FUNDING MALARIA RESEARCH
    • 4.4.3 DEVELOPMENT OF COMBINATION THERAPIES TO ENHANCE TREATMENT EFFICACY
    • 4.4.4 EMERGENCE OF REGIONAL MANUFACTURING HUBS TO BOOST SUPPLY CHAIN RESILIENCE
    • 4.4.5 IMPACT ON OVERALL HEALTHCARE SECTOR
    • 4.4.6 IMPACT ON GLOBAL ARTESUNATE INJECTION MARKET
    • 4.4.7 IMPACT ON THE SUPPLY CHAIN OF THE ARTESUNATE INJECTION MARKET
    • 4.4.8 IMPACT ON MARKET DEMAND OF ARTESUNATE INJECTION MARKET
    • 4.4.9 IMPACT ON PRICING OF ARTESUNATE INJECTION MARKET

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY CHAIN ANALYSIS
    • 5.1.1 RAW MATERIAL SUPPLIERS
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION AND LOGISTICS
    • 5.1.4 RETAIL AND CONSUMPTION
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF BUYERS
    • 5.2.3 THREAT OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTES
    • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY

  • 6.1 INTRODUCTION
  • 6.2 ARTESUNATE 0.99
  • 6.3 ARTESUNATE 0.98

7 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • 7.1.1 MALARIA
    • 7.1.2 SEVERE MALARIA
    • 7.1.3 CEREBRAL MALARIA
    • 7.1.4 UNCOMPLICATED MALARIA

8 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER

  • 8.1 INTRODUCTION
    • 8.1.1 HOSPITALS
    • 8.1.2 CLINICS
    • 8.1.3 PHARMACIES
    • 8.1.4 GOVERNMENT INSTITUTIONS
    • 8.1.5 NON-GOVERNMENTAL ORGANIZATIONS

9 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL

  • 9.1 INTRODUCTION
    • 9.1.1 DIRECT SALES
    • 9.1.2 DISTRIBUTORS AND WHOLESALERS
    • 9.1.3 RETAIL PHARMACIES
    • 9.1.4 ONLINE SALES

10 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
  • 10.3 EUROPE
  • 10.4 ASIA PACIFIC
  • 10.5 SOUTH AMERICA
  • 10.6 MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 MARKET SHARE ANALYSIS, 2023
  • 11.3 COMPETITOR DASHBOARD
  • 11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 11.4.1 LAUNCH DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 AMIVAS
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 TYPES OFFERED
    • 12.1.3 SWOT ANALYSIS
    • 12.1.4 KEY STRATEGY
  • 12.2 ADVACARE PHARMA
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 TYPES OFFERED
    • 12.2.3 SWOT ANALYSIS
    • 12.2.4 KEY STRATEGY
  • 12.3 ZYDUS CADILA
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 TYPES OFFERED
    • 12.3.3 SWOT ANALYSIS
    • 12.3.4 KEY STRATEGY
  • 12.4 INTAS PHARMACEUTICAL
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 TYPES OFFERED
    • 12.4.3 SWOT ANALYSIS
    • 12.4.4 KEY STRATEGY
  • 12.5 SYSTACARE REMEDIES
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 TYPES OFFERED
    • 12.5.3 SWOT ANALYSIS
    • 12.5.4 KEY STRATEGY
  • 12.6 LEXICARE PHARMA
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 TYPES OFFERED
    • 12.6.3 SWOT ANALYSIS
  • 12.7 CIPLA
    • 12.7.1 COMPANY OVERVIEW
    • 12.7.2 TYPES OFFERED
    • 12.7.3 SWOT ANALYSIS
    • 12.7.4 KEY STRATEGY
  • 12.8 GUILIN PHARMA
    • 12.8.1 COMPANY OVERVIEW
    • 12.8.2 TYPES OFFERED
    • 12.8.3 SWOT ANALYSIS
  • 12.9 IPCA LABORATORIES
    • 12.9.1 COMPANY OVERVIEW
    • 12.9.2 TYPES OFFERED
    • 12.9.3 SWOT ANALYSIS
  • 12.10 WATRAN PHARMACEUTICALS PVT. LTD
    • 12.10.1 COMPANY OVERVIEW
    • 12.10.2 TYPES OFFERED
    • 12.10.3 SWOT ANALYSIS

LIST OF TABLES

  • TABLE 1 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD)
  • TABLE 2 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD)
  • TABLE 3 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD)
  • TABLE 4 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD)
  • TABLE 5 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION, 2018-2032 (USD)
  • TABLE 6 NORTH AMERICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD)
  • TABLE 7 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD)
  • TABLE 8 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD)
  • TABLE 9 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD)
  • TABLE 10 NORTH AMERICA ARTESUNATE INJECTION MARKET, DISTRIBUTION CHANNEL, 2018-2032 (USD)
  • TABLE 11 US ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 12 US: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD)
  • TABLE 13 US ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD)
  • TABLE 14 US ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD)
  • TABLE 15 CANADA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 16 CANADA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 17 CANADA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 18 CANADA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 19 EUROPE: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 20 EUROPE ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 21 EUROPE: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 22 EUROPE ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 23 EUROPE ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 24 ASIA PACIFIC: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 25 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 26 ASIA PACIFIC: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 27 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 28 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 29 SOUTH AMERICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 30 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 31 SOUTH AMERICA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 32 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 33 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 34 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 35 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 36 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 37 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 38 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 39 LAUNCH DEVELOPMENTS
  • TABLE 40 AMIVAS: PRODUCT OFFERED
  • TABLE 41 ADVACARE PHARMA: TYPES OFFERED
  • TABLE 42 ZYDUS CADILA: TYPES OFFERED
  • TABLE 43 INTAS PHARMACEUTICAL: TYPES OFFERED
  • TABLE 44 SYSTACARE REMEDIES: TYPES OFFERED
  • TABLE 45 LEXICARE PHARMA: TYPES OFFERED
  • TABLE 46 CIPLA: TYPES OFFERED
  • TABLE 47 GUILIN PHARMA: TYPES OFFERED
  • TABLE 48 IPCA LABORATORIES: TYPES OFFERED
  • TABLE 49 WATRAN PHARMACEUTICALS PVT. LTD: TYPES OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL ARTESUNATE INJECTION MARKET: STRUCTURE
  • FIGURE 2 GLOBAL ARTESUNATE INJECTION MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
  • FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2032)
  • FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
  • FIGURE 5 SUPPLY CHAIN ANALYSIS: GLOBAL ARTESUNATE INJECTION MARKET
  • FIGURE 7 PORTER'S FIVE FORCES MODEL: GLOBAL ARTESUNATE INJECTION MARKET
  • FIGURE 8 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 9 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, 2023 (% SHARE)
  • FIGURE 10 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 11 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, 2023 (% SHARE)
  • FIGURE 12 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 13 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, 2023 (% SHARE)
  • FIGURE 14 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 15 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023 (% SHARE)
  • FIGURE 16 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION, 2023 (% SHARE)
  • FIGURE 17 NORTH AMERICAN MARKET: SWOT ANALYSIS
  • FIGURE 18 NORTH AMERICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 19 EUROPE MARKET: SWOT ANALYSIS
  • FIGURE 20 EUROPE: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 21 ASIA PACIFIC MARKET: SWOT ANALYSIS
  • FIGURE 22 ASIA PACIFIC: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 23 SOUTH AMERICA MARKET: SWOT ANALYSIS
  • FIGURE 24 SOUTH AMERICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 25 MIDDLE EAST & AFRICA MARKET: SWOT ANALYSIS
  • FIGURE 26 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 27 GLOBAL ARTESUNATE INJECTION PLAYERS: COMPETITIVE ANALSIS, 2023
  • FIGURE 28 COMPETITOR DASHBOARD: GLOBAL ARTESUNATE INJECTION
  • FIGURE 29 AMIVAS: SWOT ANALYSIS
  • FIGURE 30 ADVACARE PHARMA: SWOT ANALYSIS
  • FIGURE 31 ZYDUS CADILA: SWOT ANALYSIS
  • FIGURE 32 INTAS PHARMACEUTICAL: SWOT ANALYSIS
  • FIGURE 33 SYSTACARE REMEDIES: SWOT ANALYSIS
  • FIGURE 34 LEXICARE PHARMA: SWOT ANALYSIS
  • FIGURE 35 CIPLA: SWOT ANALYSIS
  • FIGURE 36 GUILIN PHARMA: SWOT ANALYSIS
  • FIGURE 37 IPCA LABORATORIES: SWOT ANALYSIS
  • FIGURE 38 WATRAN PHARMACEUTICALS PVT. LTD: SWOT ANALYSIS